Developing and validating a drug recommendation system based on tumor microenvironment and drug fingerprint
IntroductionTumor heterogeneity significantly complicates the selection of effective cancer treatments, as patient responses to drugs can vary widely. Personalized cancer therapy has emerged as a promising strategy to enhance treatment effectiveness and precision. This study aimed to develop a perso...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Artificial Intelligence |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/frai.2024.1444127/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590539596234752 |
|---|---|
| author | Yan Wang Xiaoye Jin Rui Qiu Bo Ma Sheng Zhang Xuyang Song Jinxi He |
| author_facet | Yan Wang Xiaoye Jin Rui Qiu Bo Ma Sheng Zhang Xuyang Song Jinxi He |
| author_sort | Yan Wang |
| collection | DOAJ |
| description | IntroductionTumor heterogeneity significantly complicates the selection of effective cancer treatments, as patient responses to drugs can vary widely. Personalized cancer therapy has emerged as a promising strategy to enhance treatment effectiveness and precision. This study aimed to develop a personalized drug recommendation model leveraging genomic profiles to optimize therapeutic outcomes.MethodsA content-based filtering algorithm was implemented to predict drug sensitivity. Patient features were characterized by the tumor microenvironment (TME), and drug features were represented by drug fingerprints. The model was trained and validated using the Genomics of Drug Sensitivity in Cancer (GDSC) database, followed by independent validation with the Cancer Cell Line Encyclopedia (CCLE) dataset. Clinical application was assessed using The Cancer Genome Atlas (TCGA) dataset, with Best Overall Response (BOR) serving as the clinical efficacy measure. Two multilayer perceptron (MLP) models were built to predict IC50 values for 542 tumor cell lines across 18 drugs.ResultsThe model exhibited high predictive accuracy, with correlation coefficients (R) of 0.914 in the training set and 0.902 in the test set. Predictions for cytotoxic drugs, including Docetaxel (R = 0.72) and Cisplatin (R = 0.71), were particularly robust, whereas predictions for targeted therapies were less accurate (R < 0.3). Validation with CCLE (MFI as the endpoint) showed strong correlations (R = 0.67). Application to TCGA data successfully predicted clinical outcomes, including a significant association with 6-month progression-free survival (PFS, P = 0.007, AUC = 0.793).DiscussionThe model demonstrates strong performance across preclinical datasets, showing its potential for real-world application in personalized cancer therapy. By bridging preclinical IC50 and clinical BOR endpoints, this approach provides a promising tool for optimizing patient-specific treatments. |
| format | Article |
| id | doaj-art-6d6eb5bb9ed74715ae84cf1c9dffd469 |
| institution | Kabale University |
| issn | 2624-8212 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Artificial Intelligence |
| spelling | doaj-art-6d6eb5bb9ed74715ae84cf1c9dffd4692025-01-23T11:42:37ZengFrontiers Media S.A.Frontiers in Artificial Intelligence2624-82122025-01-01710.3389/frai.2024.14441271444127Developing and validating a drug recommendation system based on tumor microenvironment and drug fingerprintYan Wang0Xiaoye Jin1Rui Qiu2Bo Ma3Sheng Zhang4Xuyang Song5Jinxi He6Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, ChinaDepartment of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, ChinaGeneral Thoracic Surgery, General Hospital of Ningxia Medical University, Yinchuan, ChinaGeneral Thoracic Surgery, General Hospital of Ningxia Medical University, Yinchuan, ChinaGeneral Thoracic Surgery, General Hospital of Ningxia Medical University, Yinchuan, ChinaGeneral Thoracic Surgery, General Hospital of Ningxia Medical University, Yinchuan, ChinaGeneral Thoracic Surgery, General Hospital of Ningxia Medical University, Yinchuan, ChinaIntroductionTumor heterogeneity significantly complicates the selection of effective cancer treatments, as patient responses to drugs can vary widely. Personalized cancer therapy has emerged as a promising strategy to enhance treatment effectiveness and precision. This study aimed to develop a personalized drug recommendation model leveraging genomic profiles to optimize therapeutic outcomes.MethodsA content-based filtering algorithm was implemented to predict drug sensitivity. Patient features were characterized by the tumor microenvironment (TME), and drug features were represented by drug fingerprints. The model was trained and validated using the Genomics of Drug Sensitivity in Cancer (GDSC) database, followed by independent validation with the Cancer Cell Line Encyclopedia (CCLE) dataset. Clinical application was assessed using The Cancer Genome Atlas (TCGA) dataset, with Best Overall Response (BOR) serving as the clinical efficacy measure. Two multilayer perceptron (MLP) models were built to predict IC50 values for 542 tumor cell lines across 18 drugs.ResultsThe model exhibited high predictive accuracy, with correlation coefficients (R) of 0.914 in the training set and 0.902 in the test set. Predictions for cytotoxic drugs, including Docetaxel (R = 0.72) and Cisplatin (R = 0.71), were particularly robust, whereas predictions for targeted therapies were less accurate (R < 0.3). Validation with CCLE (MFI as the endpoint) showed strong correlations (R = 0.67). Application to TCGA data successfully predicted clinical outcomes, including a significant association with 6-month progression-free survival (PFS, P = 0.007, AUC = 0.793).DiscussionThe model demonstrates strong performance across preclinical datasets, showing its potential for real-world application in personalized cancer therapy. By bridging preclinical IC50 and clinical BOR endpoints, this approach provides a promising tool for optimizing patient-specific treatments.https://www.frontiersin.org/articles/10.3389/frai.2024.1444127/fulltumor microenvironmentdrug fingerprintIC50MFIBest Overall Response |
| spellingShingle | Yan Wang Xiaoye Jin Rui Qiu Bo Ma Sheng Zhang Xuyang Song Jinxi He Developing and validating a drug recommendation system based on tumor microenvironment and drug fingerprint Frontiers in Artificial Intelligence tumor microenvironment drug fingerprint IC50 MFI Best Overall Response |
| title | Developing and validating a drug recommendation system based on tumor microenvironment and drug fingerprint |
| title_full | Developing and validating a drug recommendation system based on tumor microenvironment and drug fingerprint |
| title_fullStr | Developing and validating a drug recommendation system based on tumor microenvironment and drug fingerprint |
| title_full_unstemmed | Developing and validating a drug recommendation system based on tumor microenvironment and drug fingerprint |
| title_short | Developing and validating a drug recommendation system based on tumor microenvironment and drug fingerprint |
| title_sort | developing and validating a drug recommendation system based on tumor microenvironment and drug fingerprint |
| topic | tumor microenvironment drug fingerprint IC50 MFI Best Overall Response |
| url | https://www.frontiersin.org/articles/10.3389/frai.2024.1444127/full |
| work_keys_str_mv | AT yanwang developingandvalidatingadrugrecommendationsystembasedontumormicroenvironmentanddrugfingerprint AT xiaoyejin developingandvalidatingadrugrecommendationsystembasedontumormicroenvironmentanddrugfingerprint AT ruiqiu developingandvalidatingadrugrecommendationsystembasedontumormicroenvironmentanddrugfingerprint AT boma developingandvalidatingadrugrecommendationsystembasedontumormicroenvironmentanddrugfingerprint AT shengzhang developingandvalidatingadrugrecommendationsystembasedontumormicroenvironmentanddrugfingerprint AT xuyangsong developingandvalidatingadrugrecommendationsystembasedontumormicroenvironmentanddrugfingerprint AT jinxihe developingandvalidatingadrugrecommendationsystembasedontumormicroenvironmentanddrugfingerprint |